Amgen angekündigt Die Finanzergebnisse für das erste Quartal 2024 wurden am 2. Mai veröffentlicht, und die Aktien des Unternehmens stiegen unmittelbar nach der Ankündigung sprunghaft an, woraufhin kurz darauf die FDA-Zulassung eines Lungenkrebsmedikaments folgte. „Viele unserer innovativen Produkte verzeichnen ein starkes Wachstum und in unserer Pipeline entwickeln sich vielversprechende neue Medikamente weiter. Wir freuen uns… Wert der Amgen-Aktie stieg nach Finanzergebnissen und Ankündigung eines neuen Medikaments

A new Canadian study of people living with IBD found that approximately half of study participants suffered from suboptimally controlled disease, which can be connected to lower quality of life.1 The study, published in the scientific journal Digestive Diseases and Sciences, found that 52 percent (45/87)* of people living with Crohn’s disease had suboptimally controlled disease, while  43 percent (33/76)* of people living with ulcerative colitis had sub-optimally controlled disease. The IBD PODCAST study (Proportion Of inadequate Disease Control And Strategy of Treatment in IBD), which was initiated and supported by AbbVie, assessed in a real clinical practice whether patients with IBD were achieving disease control as measured by the STRIDE-II guideline recommendations**, and the impact on their quality of life.2 The Canadian PODCAST study was part of a broader analysis that included over 2,000 patients across 10 countries.2 Study…